

46

47 **Abstract (298)**

48 **Introduction** Detection of *Mycobacterium tuberculosis* (*Mtb*) in patient-derived bioaerosol is a potential tool to
49 measure source case infectiousness. However, current bioaerosol sampling approaches have reported low
50 detection yields in sputum-positive TB cases. To increase the utility of bioaerosol sampling, we present
51 advances in bioaerosol collection and *Mtb* identification that improve detection yields.

52 **Methods** A previously described Respiratory Aerosol Sampling Chamber (RASC) protocol, or “RASC-1”, was
53 modified to incorporate liquid collection of bioaerosol using a high-flow wet-walled cyclone (RASC-2).
54 Individuals with GeneXpert-positive pulmonary TB were sampled pre-treatment over 60-minutes. Putative *Mtb*
55 bacilli were detected in collected fluid by fluorescence microscopy utilising DMN-Trehalose. Exhaled air and
56 bioaerosol volumes were estimated using continuous CO₂ monitoring and airborne particle counting,
57 respectively. *Mtb* capture was calculated per exhaled air volume sampled and bioaerosol volume for RASC-1
58 (n=35) and for RASC-2 (n=21). Empty chamber samples were collected between patients as controls.

59 **Results** The optimised RASC-2 protocol sampled a median of 258.4L (IQR: 226.9-273.6) of exhaled air per
60 patient compared with 27.5L (IQR: 23.6-30.3) for RASC-1 (p<0.0001). Bioaerosol volume collection was
61 estimated at 2.3nL (IQR: 1.1-3.6) for RASC-2 compared with 0.08nL (IQR: 0.05-0.10) for RASC-1 (p<0.0001).
62 The detection yield of viable *Mtb* improved from 43% (median 2 CFU, range: 1-14) to 95% (median 20.5
63 DMN-Trehalose positive bacilli, range: 2-155). These improvements represent a lowering of the limit of
64 detection in the RASC-2 platform to 0.9 *Mtb* bacilli per 100L of exhaled air from 3.3 *Mtb* bacilli per 100L
65 (RASC-1).

66 **Conclusion** This study demonstrates that technical improvements in particle collection together with sensitive
67 detection enable rapid quantitation of viable *Mtb* in bioaerosols of sputum positive TB cases. Increased
68 sampling sensitivity may allow future TB transmission studies to be extended to sputum-negative and
69 subclinical individuals, and suggests the potential utility of bioaerosol measurement for rapid intervention in
70 other airborne infectious diseases.

71 **Introduction**

72 Tuberculosis (TB) remains a serious global public health threat [1]. In 2018, the global incidence was estimated
73 at 10 million with a death toll of 1.5 million [2]. Driving the high burden is on-going transmission of infection,
74 as demonstrated by the 1.1 million cases of childhood TB disease globally. Further evidence for the prominence

75 of transmission comes from molecular epidemiology studies in high-prevalence countries which have
76 highlighted that the majority of TB disease follows from recent *Mtb* infection [3].

77 Transmission events are influenced by many factors which relate to the source case, the bacillus, the
78 environment and the host. Fundamental to transmission, however, is the production of aerosolized *Mtb*: in the
79 absence of aerosol release, no transfer of infectious organisms between individuals can occur. Pioneering
80 experiments performed by Wells and Riley more than 60 years ago utilized the guinea pig as an aerosol sampler,
81 detecting transmission by the demonstration of new infection in the animals [4, 5]. Employing a sampling
82 system with physical separation of patients (source case) and guinea pigs (sampler) led to the confirmation of
83 airborne transmission. Moreover, intricate linking of individual patients to specific guinea pig infections by
84 bacillary resistance patterns and timing of entry and departure from the ward allowed for identification of a
85 minority of highly infectious ‘super-spreaders’. The guinea pig model therefore supported the concepts that
86 infectiousness is highly heterogenous and that small bioaerosol – which arise as a consequence of dehydration
87 of buoyant airborne droplets during “aging” following release into the environment –are primarily responsible
88 for remote transmission [6].

89 Invaluable though this contribution was to the early understanding of TB transmission, the experimental design
90 was not optimised for sensitive sampling [7]. Minimal sensitivity to *Mtb* production necessitates sampling
91 multiple patients for days to months for both historical and recent *in vivo* sampling experiments [8-10].
92 However, some modern approaches with greater proximity between source case and sampler, single patient
93 sampling and viable organism detection have dramatically improved the overall detection sensitivity. Direct
94 detection has identified *Mtb* bacilli within only minutes to hours of sampling [11-13], generated individual-level
95 information, and found a greater proportion of emitters.

96 These sensitive techniques have the potential to efficiently answer questions regarding the transmission
97 potential of patient sub-groups and test strategies for transmission mitigation. Further sensitivity improvement
98 may allow investigation of *Mtb*-containing droplet release from patients across the TB disease spectrum,
99 including sputum smear-negative cases, HIV-coinfected and even subclinical TB cases. Sensitive sampling
100 combined with quantitative forms of detection also provide an infectivity measure. Such a measure could be
101 applied longitudinally to those receiving chemotherapy to more accurately establish time to bioaerosol
102 sterilisation with direct clinical application.

103 We describe a direct bioaerosol sampling device designed to collect aged aerosol. We have attempted to
104 optimise key components necessary to maximise detection yield through an iterative re-design process.
105 Preliminary results of sampling from both healthy controls and individuals with newly diagnosed pulmonary TB
106 are also presented.

107 **Materials and Methods**

108 The Respiratory Aerosol Sampling Chamber (RASC) is an enclosed, clean room optimised for the sampling of
109 aged bioaerosol from a single individual during a 60-minute period of natural respiratory activity. A previous
110 description of the RASC design, “RASC-1”, has been published [14] in addition to results from a 35-patient
111 pulmonary TB sampling study [11]. The apparatus and sampling protocols employed for those initial studies is
112 referred to throughout this report as “RASC-1”. The current study describes several design modifications,
113 informed by an iterative series of experiments, which have refined the apparatus and sampling protocol while
114 maintaining the basic structure of the chamber. This new version is referred to as “RASC-2”.

115 **Sample Collection**

116 RASC-1 included an array of aerosol sample collection instruments operated consecutively at the peak of
117 chamber air contamination. This included polycarbonate, gelatin and felt filters, Dekati and Andersen impactors,
118 and a cyclone collector. The flow rates (chamber outflow) varied between instruments, subject to device
119 specifications. Both impactors and the polycarbonate and gelatin filters sampled with flow rates of 20-30 L/min,
120 whereas the felt filter and the cyclone collector sampled with higher flow rates: 300 and 250 L/min,
121 respectively. Results yielded no positive samples from the felt or gelatin filters. For the rest, no sampling
122 instruments demonstrated significantly higher yield per unit of exhaled air sampled. Therefore, to maximize the
123 exhaled air volume sampled, the sample collection process was simplified to a single cyclone collector.

124 **Cyclone Collector**

125 A high-efficiency cyclone collector (Coriolis μ air sampler, Bertin, Montigny le Bretonneux, France) was used
126 for RASC-2 to collect airborne bioaerosol into 5-10 mL of sterile phosphate-buffered saline (PBS) solution.
127 Mounted within the chamber, the air enters the conical collector through a tangential nozzle. The high flow rate
128 of 250 L/min generates a liquid cyclone and particle inertia leads to deposition of bioaerosol from the airstream
129 onto the wet wall with a high collection efficiency. Collection into liquid has the advantage of minimizing
130 particle bounce, improving the recovery of viable *Mtb* bacilli and maximizing the air volume sampled over time.

131 **Sampling Protocol**

132 The experimental protocol was modified to continuous sampling of the chamber air via the single high-flow
133 (250 L/min) cyclone collector. This replaces the sequential sampling phases of the RASC-1 protocol.
134 Consequently, there is a lowering of the CO₂ set-point throughout the protocol and improved regulation of
135 chamber humidity and temperature, illustrated by the CO₂ traces in Figure 1. This effect primarily maximizes
136 the air volume sampled by reducing the loss of exhaled air at the end of the study protocol. There is an added
137 benefit of improved thermal comfort for participants.

138 **Figure 1.** Differing example CO₂ traces for the two sampling protocols (A) RASC-1: initial contamination and
139 short, steady-state sampling (median 3800 PPM CO₂). (B) RASC-2: continuous sampling with a lower steady-
140 state (median 1600 PPM CO₂).
141

142 ***Mtb* Detection**

143 Liquid specimen collection facilitates sample concentration via centrifugation and the application of culture-
144 independent detection techniques. For the RASC-2 protocol, the centrifuged bioaerosol sample pellet was
145 incubated with a novel solvatochromic trehalose analog, DMN-Trehalose, which was incorporated into the cell
146 walls of metabolically active mycobacteria, and subsequently yielding high fluorescence intensity detectable by
147 a fluorescence microscope [15]. Each participant sample was added to a microwell device (Edge Technologies,
148 USA) containing an array of 1600 nanowells measuring 50 x 50 µm. This generated multiple discrete
149 microenvironments for *Mtb* detection and avoided overgrowth of contaminants affecting the whole sample [16].
150 Fluorescent microscopy employed a skilled operator to distinguish *Mtb* on the basis of bacillus morphology and
151 specific staining patterns.

152 **CO₂ and Bioaerosol Monitoring**

153 Continuous CO₂ and aerodynamic particle monitoring of the chamber air was performed in both sampling
154 protocols, RASC-1 and RASC-2. Estimates of captured *Mtb* bacilli per unit volume of exhaled air and per unit
155 volume of respiratory bioaerosol were calculated using the method described in the previous (RASC-1) study
156 [12].

157 **Study Participants**

158 All recruited participants were residents from two informal peri-urban settlements outside Cape Town and in
159 close proximity to the study site. Eligible candidates were those with GeneXpert-positive sputum without
160 evidence of drug resistance. Bioaerosol sampling was performed before initiation of anti-tuberculous therapy, as
161 per the approved Ethics protocol (see below). The empty chamber was sampled between human participants to
162 serve as chamber decontamination controls. Baseline patient data were collected from the clinical records and a

163 chest X-ray was taken approximately seven days after the start of treatment. The presence of lung cavitation was
164 scored by one of the authors (BP) based on the chest X-ray and this score was compared to a radiologist report
165 for agreement.

166 **Statistical Analysis**

167 The performance of the RASC-2 protocol was compared with the original RASC-1 design in terms of the
168 exhaled air volume and bioaerosol volume sampled and *Mtb* bacilli captured. Comparison between the protocols
169 was made with a Wilcoxon rank sum test. Statistical analyses were performed using R Core Team (2019).

170

171 **Ethical statement**

172 The patient studies are covered by two separate ethics approvals from the University of Cape Town Faculty of
173 Health Sciences Human Research Ethics Committee (HREC/REF: 680/2013; HREC/REF: 529/2019). Each
174 patient provided written informed consent prior to participation in the study, including consent to publication of
175 the clinical and demographic details.

176 **Results**

177 **Patient Characteristics**

178 Individuals were consecutively recruited from the same two communities. The RASC-1 protocol was
179 implemented over the time period 2015 to 2017 and RASC-2 from 2018 to 2019. Table 1 compares basic
180 clinical and demographic characteristics, confirming broad equivalence between patients sampled by the two
181 protocols.

182 **Table 1.** Comparison of baseline patient characteristics between RASC-1 and RASC-2.

183

184 **RASC Comparison**

185 The two RASC designs were compared using indicators of sampling efficiency (Fig. 2A and 2B) and numbers
186 of *Mtb* bacilli captured (Fig. 2C). The sampled volume of exhaled air was calculated using continuous CO₂
187 measurement to determine exhaled air proportion in chamber air during device sampling. Similarly, chamber
188 bioaerosol concentration was determined by particle counting and volume calculation with the assumption that
189 bioaerosol are spherical. Captured bioaerosol volume was estimated by assuming completely efficient sampling
190 of this concentration. Both these methods have been described previously [11].

191 **Figure 2.** Comparative efficiencies of RASC-1 versus RASC-2 in capture of exhaled air (A), collection of
192 bioaerosol volume (B), and capture of *Mtb* organisms (C). Note that numbers in (C) were determined by colony
193 forming units (RASC-1) and DMN-Trehalose-positive organisms identified using fluorescence microscopy
194 (RASC-2).
195

196 **RASC Decontamination**

197 As mentioned previously [14], the highly sensitive *Mtb* detection methodology used in RASC-2 is vulnerable to
198 contamination owing to incomplete sterilization of the chamber. To control for this risk, patient sampling was
199 interspersed with empty RASC sampling. Detected organisms in the control samples suggested a small degree
200 of contamination. Figure 3 demonstrates the different bacillary counts for patient sampling and empty RASC
201 sampling. Control samples remained negative after modification of the collector design and high concentration
202 ozone sterilization of the RASC.

203 **Figure 3.** Comparison of total bacillary counts following RASC-2 sampling of sputum GeneXpert-positive TB
204 patients (n=21) and the inter-patient empty booth RASC sampling controls (n=22). P<0.0001.
205

206 **Limit of Detection**

207 A bacillary count per unit volume of exhaled air was calculated and compared between the two sampling
208 protocols. Figure 4 illustrates the range of detectable concentrations across the sampled populations. Notably, by
209 combining the design improvements, the limit of detection has been lowered from approximately 3.3 bacilli per
210 100 L exhaled air to 0.9 bacillus per 100 L.

211 **Figure 4.** *Mtb* bacillary counts per 100 L exhaled air for RASC-1 versus RASC-2. Sampled individuals not
212 yielding detectable *Mtb* bacilli are illustrated by points on the x-axis.

213 **Discussion**

214 This study has shown that, by optimising both bioaerosol collection and *Mtb* detection, a majority of newly
215 diagnosed GeneXpert sputum positive TB patients can be shown to exhale viable *Mtb* organisms. The increased
216 numbers of *Mtb* organisms captured by RASC-2 compared with RASC-1 were associated with an approximate 1
217 log₁₀ increase in exhaled air sampled and bioaerosol particle volume collected. This is not explained by
218 demographic and clinical characteristics which were broadly equivalent between the patients sampled by the
219 different methods. The resulting lowered limit of detection enabled identification of putative *Mtb* organisms in
220 95% of patients whose bacillary concentrations varied over a 2 log₁₀ range from 1 to 100 per 100 L exhaled air.
221 The proportion of patients identified with *Mtb* positive bioaerosols is therefore a function of lower level of
222 detection. However, exhaled particle volumes varied markedly between individuals, suggesting that infectivity
223 is likely to be impacted by both *Mtb* concentration of lung fluids and individual bioaerosol particle production.

224 The current study sampled newly diagnosed TB patients while seated in a small personalized clean room with
225 normal respiration and spontaneous coughing over 60-minutes. Collected bioaerosol were those which remained
226 airborne in the RASC and, at time of collection, were predominantly in the 1-5 μm diameter range. Consistent
227 with prior observations [6], these are the particles thought most likely to reach the peripheral lungs of
228 susceptible individuals sharing an indoor location [17]. It is also probable that these bioaerosols containing
229 viable *Mtb* organisms might be indicative of a wide range of source infectivity. The investigation of *Mtb*
230 production and, consequently, potential infectivity during various respiratory manoeuvres is under current
231 investigation in our laboratory.

232 The sensitive detection of individual *Mtb* organisms, with DMN-Trehalose staining and subsequent fluorescence
233 microscopy analysis, requires a high degree of sterility to exclude contamination during sampling and isolation.
234 After detailed analysis of the platform and collection equipment, we noted that the wet-walled cyclone
235 contained a dead space which was a potential reservoir for live *Mtb* cells. Therefore, the device was modified to
236 enable dismantling and autoclaving. The very low numbers of *Mtb* organisms detected during empty booth
237 sampling could also have resulted from the release of trapped *Mtb* organisms by the negative pressure inducing
238 retrograde airflow across the exit HEPA filter. Reassuringly, following modification of the collector and the
239 application of combined dry vapour hydrogen peroxide and ozone treatments of the RASC after use, the empty
240 booth controls remained negative.

241 **Conclusion**

242 The development of a sensitive and reproducible measure of *Mtb* in exhaled bioaerosols has enabled the
243 demonstration of a wide range of potential infectivity of newly diagnosed TB patients. Bioaerosol assays may
244 offer a useful adjunct to TB transmission studies, enabling demonstration of infectivity of sputum negative
245 individuals and the effect of specific chemotherapies on infectivity. Moreover, the protocols and equipment
246 described here suggest the potential application of this technology to other airborne infectious diseases,
247 especially where rapid interventions such as containment and quarantine are required to curb outbreaks [18].

248 **References**

249 [1] Wood R, Lawn SD, Caldwell J, Kaplan R, Middelkoop K, Bekker L-G. (2011) Burden of New and
250 Recurrent Tuberculosis in a Major South African City Stratified by Age and HIV-Status. *PLoS ONE*;
251 6(10):e25098. doi: 10.1371/journal.pone.0025098

252

253 [2] World Health Organization, Global Tuberculosis Report (2019). Geneva: World Health Organization.

254 [3] Middelkoop, K., Mathema, B., Myer, L., Shashkina, E., Whitelaw, A., Kaplan, G., Kreiswirth, B., et al.

255 (2015). Transmission of Tuberculosis in a South African Community With a High Prevalence of HIV Infection.

256 *J Infect Dis.*, 211(1), 53–61. Retrieved March 2, 2020, from 10.1093/infdis/jiu403

257 [4] Riley, R. L. *et al.* Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a

258 tuberculosis ward. *Am J Epidemiol* **142**, 3-14 (1959).

259

260 [5] Sultan, L. *et al.* Tuberculosis disseminators. A study of the variability of aerial infectivity of tuberculous

261 patients. *Am Rev Respir Dis* **82**, 358-369, doi:10.1164/arrd.1960.82.3.358 (1960).

262

263 [6] Donald, P. R., Diacon, A. H., Lange, C., Demers, A.-M., von Groote-Biddlingmeier, F., & Nardell, E.

264 (2018). Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878–1940.

265 *int j tuberc lung dis*, 22(9), 972–982. Retrieved March 2, 2020, from 10.5588/ijtld.18.0173

266 [7] M Issarow, C., & Wood, R. (2016). Seminal Mycobacterium Tuberculosis in vivo Transmission Studies:

267 Reanalysis Using Probabilistic Modelling. *Mycobact Dis*, 6(3). Retrieved January 12, 2020a, from

268 10.4172/2161-1068.1000217

269 [8] Riley RL, Mills CC, Nyka WN, Storey PB, Sultan LU, et al. (1959) Aerial dissemination of pulmonary

270 tuberculosis: A two-year study of contagion in a tuberculosis ward. *American Journal of Epidemiology* 70: 185-

271 196.

272 [9] Dharmadhikari, A. S., Basaraba, R. J., Van Der Walt, M. L., Weyer, K., Mphahlele, M., Venter, K., Jensen,

273 P. A., et al. (2011). Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis.

274 *Tuberculosis*, 91(4), 329–338. Retrieved March 2, 2020, from 10.1016/j.tube.2011.03.002

275 [10] Escombe AR, Moore DA, Gilman RH, Pan W, Navincopa M, et al. (2008) The Infectiousness of



276 tuberculosis patients co-infected with HIV. *PLoS Med* 5: e188.

277 [11] Patterson, B., Morrow, C., Singh, V., Moosa, A., Gqada, M., Woodward, J., Mizrahi, V., et al. (2017).


278 Detection of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients. *Gates Open Res*, 1,

279 11. Retrieved March 2, 2020, from 10.12688/gatesopenres.12758.2


- 280 [12] Fennelly, K. P., Martyny, J. W., Fulton, K. E., Orme, I. M., Cave, D. M., & Heifets, L. B. (2004). Cough-
281 generated Aerosols of *Mycobacterium tuberculosis*. *Am J Respir Crit Care Med*, *169*(5), 604–609. Retrieved
282 March 2, 2020, from [10.1164/rccm.200308-1101oc](https://doi.org/10.1164/rccm.200308-1101oc)
- 283 [13] Williams, C. M. L., Cheah, E. S. G., Malkin, J., Patel, H., Otu, J., Mlaga, K., Sutherland, J. S., et al. (2014).
284 Face Mask Sampling for the Detection of *Mycobacterium tuberculosis* in Expelled Aerosols. *PLoS ONE*, *9*(8),
285 e104921. Retrieved March 2, 2020, from [10.1371/journal.pone.0104921](https://doi.org/10.1371/journal.pone.0104921)
- 286 [14] Wood, R., Morrow, C., Barry, C. E., Bryden, W. A., Call, C. J., Hickey, A. J., Rodes, C. E., et al. (n.d.).
287 Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber
288 (RASC). *PLoS ONE*, *11*(1), e0146658. Retrieved March 2, 2020, from [10.1371/journal.pone.0146658](https://doi.org/10.1371/journal.pone.0146658)
- 289 [15] Kamariza, M., Shieh, P., Ealand, C. S., Peters, J. S., Chu, B., Rodriguez-Rivera, F. P., Babu Sait, M. R., et
290 al. (2018). Rapid detection of *Mycobacterium tuberculosis* in sputum with a solvatochromic trehalose probe.
291 *Sci. Transl. Med.*, *10*(430), eaam6310. Retrieved March 2, 2020, from [10.1126/scitranslmed.aam6310](https://doi.org/10.1126/scitranslmed.aam6310)
- 292 [16] Ryan Dinkele, Sophia Gessner, Anastasia Koch et al. Capture and visualization of live *Mycobacterium*
293 *tuberculosis* bacilli from tuberculosis bioaerosols.
294 *bioRxiv* 2019.12.23.887729; doi: <https://doi.org/10.1101/2019.12.23.887729>
- 295 [17] Brown, J. S., Gordon, T., Price, O., & Asgharian, B. (2013). Thoracic and respirable particle definitions for
296 human health risk assessment. *Particle and Fibre Toxicology*, *10*(1), 12. Retrieved March 2, 2020, from
297 [10.1186/1743-8977-10-12](https://doi.org/10.1186/1743-8977-10-12)
- 298 [18] Wu, J. T., Leung, K., & Leung, G. M. (2020). Nowcasting and forecasting the potential domestic and
299 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet*,
300 *395*(10225), 689–697. Retrieved March 2, 2020, from [10.1016/s0140-6736\(20\)30260-9](https://doi.org/10.1016/s0140-6736(20)30260-9)
- 301
- 302

A**RASC-1 Protocol****B****RASC-2 Protocol**


Exhaled Air Collected (Liters)



Biomass Volume Collected (mL)



Mfb Count




DMN-free Stained Bacilli Count

150
100
50
0

Empty RASG


Patients




Count per 100 Liters of Exhaled Air

RASC 1 (MTS CPU)

RASC 2 (GMH-The Shared MTS Facility)



Participant



	RASC -1	RASC -2	p-value
n	35	21	
Age			
median [IQR]	32 [25, 39]	35 [31, 41]	0.23
Sex			
Male (%)	20 (57.1)	14 (77.8)	0.24
HIV Status			
Positive (%)	17 (48.6)	6 (28.6)	0.23
CD4 ⁺ Count			
median [IQR]	122 [63, 417]	90 [49, 146]	0.51
Sputum GeneXpert			
Positive (%)	35 (100)	21 (100)	N/A
Previous TB			
Yes (%)	11 (31.4)	5 (23.8)	0.76
Cavitation			
Present (%)	13 (39.4)	6 (46.2)	0.93